Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol
作者:V Nair、M H St Clair、J E Reardon、H C Krasny、R J Hazen、M T Paff、L R Boone、M Tisdale、I Najera、R E Dornsife
DOI:10.1128/aac.39.9.1993
日期:1995.9
IsoddA-resistant virus (eightfold-increased 50% inhibitory concentration) was selected in vitro by repeated passage of HIV-1 (HXB2) in the presence of increasing concentrations of IsoddA. The reverse transcriptase-coding region of the mutant virus contained a single base change resulting in a change at codon 184 from Met to Val. IsoddA was also active against hepatitis B virus (HBV) in vitro; however, it
4(S)-(6-氨基-9H-嘌呤-9-基)四氢-2(S)-呋喃甲醇(IsoddA)是一类新型旋光异构二脱氧核苷中最抗病毒的成员从自然的1'位置转置为2'位置,并且绝对构型为(S,S)。IsoddA对人免疫缺陷病毒1型(HIV-1)(IIIB株),HIV-2(ZY株)和HIV-1临床分离株具有活性。该化合物与齐多夫定(3'-叠氮基-3'-脱氧胸苷),2',3'-二脱氧肌苷或5-氟-2'-脱氧-3'-硫代胞苷的组合显示出对HIV的协同抑制作用。用对齐多夫定耐药的临床分离株观察到活性适度降低。通过在增加的IsoddA浓度下重复传播HIV-1(HXB2),在体外选择对IsoddA耐药的病毒(抑制浓度增加8倍)。突变病毒的逆转录酶编码区包含单个碱基变化,导致第184位密码子从Met变为Val。IsoddA在体外还具有抗乙型肝炎病毒(HBV)的活性;然而,它在体内HBV模型中缺乏实质的选择性活性。Is